Full-Time

Breast Reconstruction Specialist

Posted on 3/12/2025

Axogen

Axogen

201-500 employees

Compensation Overview

$105kAnnually

+ Commission

Senior

San Francisco, CA, USA

The candidate must reside in the territory, which includes all of Northern California and Oregon, with a preference for being based out of San Francisco.

Category
Field Sales
Sales & Account Management
Requirements
  • BS degree required
  • Masters degree preferred
  • 5 years medical device or medical technologies sales experience required
  • Experience selling to Breast Reconstruction surgeons strongly preferred
  • Proven track record of success with back to back years top awards/accolades, top 10-15% nationwide rankings, history of promotion
  • 75% plus travel
  • Reside in the territory (see below)
Responsibilities
  • Serve as a clinical resource and expert on nerve repair and the benefits of Axogen’s products to new markets and applications’ surgeons and to the Axogen sales and marketing team
  • Develop product, clinical and technical expertise required to credibly and successfully represent Axogen and the Axogen portfolio of nerve repair products to clinicians and hospital purchasing agents
  • Demonstrate a strategic selling approach by successfully positioning and communicating a value proposition that is compelling to the sale
  • Accelerate sales of Axogen nerve repair products to surgeons and accounts in the target
  • Provide a plan and execution strategy for calling on target surgeons and
  • Facilitate stocking and ordering of Axogen products in the account to facilitate regular
  • Provide regular feedback and suggestions on market trends, training needs and potential product
  • Focus on increasing qualified leads and converting them to sustainable sales, then managing those relationships
  • Create in-field strategies to build a network between the New Market Applications’ Breast Recon Specialist, surgeons and local sales
  • Conduct cold calls and presenting/articulating the key benefits of Axogen’s products to the sales targets
  • Work in partnership with the local Axogen sales representation to meet territory
  • Assess sales target needs through active listening and provide
  • Work with new market applications’ surgery educational programs to include Axogen’s products in their microsurgical training
  • Collaborate with the marketing team to plan and execute market development events. Travelling to events and leading them as
  • Track and report contacts with customers, individual customer needs and interests and customer adoption
  • Possess the ability to engage in elevated strategic conversations with KOLs, practice and hospital administration, along with other key influencers and engage and comprehend beyond a Transactional selling opportunity
  • Will not force product to be used unnecessarily or to unqualified target due to the understanding of the greater good of initiative
  • Comprehends program and procedure economics
  • Research understand each referral stream and path of patients
  • Collaborate with the marketing team to plan and execute market development
  • Organize, attend, and lead patient/community awareness events
  • Collaborate with patient advocacy groups
  • Reach established sales and corporate

Company Size

201-500

Company Stage

IPO

Headquarters

Alachua, Florida

Founded

2002

Simplify Jobs

Simplify's Take

What believers are saying

  • The peripheral nerve repair market is projected to grow at a CAGR of 11.2% by 2030.
  • Increased focus on biologics drives innovation in Axogen's advanced grafts and tissue matrices.
  • AI integration in surgical planning offers potential enhancements in Axogen's product offerings.

What critics are saying

  • Leadership changes may disrupt ongoing projects or alter company focus.
  • Departure of experienced personnel could impact clinical research and development expertise.
  • Public offering of common stock may dilute existing shareholders' equity.

What makes Axogen unique

  • Axogen specializes in innovative surgical solutions for peripheral nerve injuries.
  • The company launched Avive+ Soft Tissue Matrix, a resorbable amniotic membrane allograft.
  • Axogen initiated a Biologics License Application for Avance Nerve Graft.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Paid Vacation

Paid Holidays

Employee Stock Purchase Plan

Tuition Reimbursement

Paid Parental Leave

Paid Caregiver Leave

Basic Life Insurance

Supplemental Life Insurance

Disability Insurance

Company News

Market Wire News
Jan 10th, 2025
AXGN - Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) - Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Craig Swandal as Vice President of Operations.

Investor Brand Network
Nov 7th, 2024
BioMedNewsBreaks - Annovis Bio Inc. (NYSE: ANVS) Strengthens Clinical Research Team with Appointment of Senior Clinical Scientist

Dr. Peterson, an experienced clinical researcher with a background in both academic and industry roles, joins from Axogen, where he specialized in therapies for peripheral nerve repair.

MedTech Dive
Aug 9th, 2024
Axogen names ex-Abbott exec Michael Dale as CEO

Axogen names ex-abbott exec Michael Dale as CEO.

GlobeNewswire
Jun 24th, 2024
Axogen, Inc Announces Full Launch Of Avive+ Soft Tissue Matrix(Tm)

ALACHUA, Fla. and TAMPA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the launch of its newest product, Avive+ Soft Tissue Matrix™. Avive+™ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is processed and distributed in accordance with U.S. Food and Drug Administration (FDA) requirements for Human Cellular and Tissue-based Products (HCT/P) under 21 CFR Part 1271 regulations, U.S

GlobeNewswire
May 16th, 2024
Axogen Inc. Initiates Rolling Submission Of Biologics License Application To U.S. Food And Drug Administration (Fda) For Avance Nerve Graft(R)

ALACHUA, Fla. and TAMPA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is pleased to announce that it has initiated the rolling submission process with the U.S. Food and Drug Administration for a Biologics License Application (BLA) for licensure of Avance Nerve Graft® on May 15, 2024.“Today’s milestone represents a significant step in our regulatory transition of Avance Nerve Graft to a biologic,” said Karen Zaderej, chairman, CEO, and president of Axogen, Inc. “I am grateful to our Axogen team and their diligence as we work towards completing the rolling BLA submission process.”The initial submission to the U.S. FDA includes the complete non-clinical data package for the BLA